7f is identified as a promising lead displaying concurrent EGFR and COX-2 inhibitory activity together with pronounced antiproliferative effects, consistent with its experimentally observed dual inhibitory activity.
Abstract
Abnormal epidermal growth factor receptor (EGFR) signaling and cyclooxygenase-2 (COX-2) mediated inflammatory pathways contribute to tumor progression and survival, supporting their simultaneous pharmacological targeting. Herein, a series of quinazolinone–diarylpyrazole hybrids 7a–l was designed, synthesized, and evaluated as dual EGFR/COX-2 inhibitors. Compound 7f exhibited the most balanced inhibitory profile against the two targets, exhibiting EGFR and COX-2 IC50 values of 0.24 ± 0.03 and 0.08 ± 0.01 µM, respectively, together with a COX-2 selectivity index of 197.88. Compound 7j displayed the highest EGFR inhibitory activity within the series (IC50 = 0.15 ± 0.02 µM). The hybrids showed marked antiproliferative activity against A431, A549, and HCA-7 cancer cells, with 7f exhibiting IC50 values of 1.18 ± 0.14, 1.42 ± 0.17, and 0.86 ± 0.17 µM, respectively, and a cellular selectivity index of 14.08 toward MRC-5 cells. Cellular studies further demonstrated that 7f inhibited cellular EGFR phosphorylation (IC50 = 0.77 ± 0.11 µM) and suppressed PGE-2 release by 89.9% at 1 µM. Moreover, 7f increased Bax expression, reduced Bcl-2 levels, and enhanced caspase-3 and caspase-9 levels, supporting induction of apoptosis. Molecular docking analyses supported favorable accommodation of 7f within the binding sites of wild-type EGFR and COX-2, consistent with its experimentally observed dual inhibitory activity. Collectively, these findings identify 7f as a promising lead displaying concurrent EGFR and COX-2 inhibitory activity together with pronounced antiproliferative effects.
A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.
Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al.· Bioorganic chemistry (Print)· 0 citations
Findings identify compound 9 as a promising multi-target quinoxaline-based agent with dual antiproliferative and anti-inflammatory activities, mediated through induction of mitochondrial apoptosis and modulation of oxidative stress and cytokine signaling pathways.
S. Alshawwa, Ghazi A. Bamagous, Hatem A. Sembawa et al.· RSC Advances· 0 citations
The synthesized benzoxazole hybrid compounds showed promising anticancer activity with acceptable ADMET properties; however, further structural optimization and mechanistic studies are needed to validate the molecular targets and improve safety and pharmacokinetic profiles.
Mahmoud A. Al-Sha'er, A. H. Abdullah, Almeqdad Y. Habashneh et al.· Chemistry Africa· 0 citations
Compound 6b is identified as a promising lead candidate for further development as a VEGFR-2-targeted anticancer agent and stable backbone behavior, regulated ligand fluctuations, preserved structural compactness, and sustained hydrogen bonding within the 6b-VEGFR-2 complex are identified.
Mohamed El-Naggar, Hend I Abdelaal, Mohamed E Albakri et al.· RSC Advances· 0 citations
G glycine conjugation of a coumarin-quinazoline hybrid has not been reported previously, and the results identify it as a substituent- and cell-line-dependent strategy for improving anticancer potency and selectivity.
N. Çalışkan, M. Emirik, F. Yılmaz et al.· Bioorganic chemistry (Print)· 2 citations
Findings highlight quinoline–triazole hybrid SVI08 as a preliminary lead to the further optimization as a VEGFR-2-targeted anticancer agents as well as acceptable ADMET properties and good in vivo tolerability up to 50 mg/kg.
Divyanshi Thakur, Mangaldip Ghosh, Shivam Nag et al.· In Silico Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.